Enanta Pharmaceuticals vs Prothena Corp Public
ENTA and PRTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENTA and PRTA compare
Prothena Corp Public is the larger company, worth 1.3 times as much as Enanta Pharmaceuticals ($419M against $320M).
Prothena Corp Public keeps more of each dollar of sales as profit, with a net margin of −45.4% compared with −96.9% at Enanta Pharmaceuticals.
Prothena Corp Public scores higher on the StockData Score (12 against 2 for Enanta Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENTA | PRTA |
|---|---|---|
| Size and price | ||
| Market cap | $320M | $419M |
| Share price | $10.99 | $8.16 |
| Change, 1 year | −7.9% | −24.8% |
| Change, 5 years | −85.4% | −86.1% |
| Beta (5Y) | 1.14 | 0.86 |
| Employees | 120 | 67 |
| StockData Score | ||
| Total score | 2 | 12 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.9× (better) | 7.9× |
| P/B | 3.2× | 1.6× (better) |
| FCF yield | −11.5% | – |
| Fair value | $9.32 | $9.83 |
| Margin of safety | −17.9% | 17.0% (better) |
| Growth | ||
| Revenue growth (TTM) | – | 347% |
| Revenue growth, 5Y average | −11.8% | 62.6% (better) |
| Profitability | ||
| Operating margin | −90.0% | −64.6% (better) |
| Net margin | −96.9% | −45.4% (better) |
| FCF margin | −56.6% | – |
| Return on equity | −70.1% | −8.5% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −4.5× | – |
| Current ratio | 3.76 | 23.95 (better) |
| Altman Z-score | −0.97 | 11.36 (better) |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 93.6% | 92.2% |
| Held by insiders | 7.9% | 32.0% |
| Insider net buying, 12 months | −$183K | $13.1M (better) |
| Short interest, % of float | 6.9% | 22.7% |
Go deeper
- ENTA stock overview
- ENTA income statement
- ENTA valuation and score
- PRTA stock overview
- PRTA income statement
- PRTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.